Suppression of Dendritic Cells by HMGB1 Is Associated with Lymph Node Metastasis of Human Colon Cancer

Akiko Kusumea Tomonori Sasahiraa Yi Luoa Mamoru Isobea
Naoya Nakagawab Naokuni Tatsumotob Kiyomo Fujia Hitoshi Ohmoria
Hiroki Kuniyasua

aDepartment of Molecular Pathology, Nara Medical University, Kashihara, bDepartment of Surgery, Miyoshi Central Hospital, Miyoshi, Japan

Key Words
HMGB1 · Dendritic cells · Apoptosis · Colon cancer

Abstract
High mobility groupbox-1 (HMGB1) is a multifunctional cytokine secreted by cancer cells, which accelerates cell growth, invasion and angiogenesis in cancer, and induces apoptosis in macrophages. Thioglycolate-stimulated mouse peritoneal macrophages were induced to differentiate into dendritic cells by co-treatment with IL-4 and GM-CSF. The number of mouse peritoneal macrophage-derived dendritic cells (PMDDCs) showed a dose-dependent decrease in hrHMGB1 treatment. HMGB1-treated PMDDCs showed obvious apoptosis and increased the level of phosphorylated JNK. Intraperitoneal administration of HMGB1 decreased CD205-positive splenic dendritic cells in C57BL mice. To confirm the HMGB1-induced inhibitory effect on dendritic cells, 16 cases of human colon cancer invaded into the subserosal layer were examined. The 8 nodal metastasis-positive cases showed higher nodal HMGB1 levels (116 ± 33 vs. 37 ± 18 μg/ml, p = 0.0007) and lower CD205-positive intratumoral dendritic cell numbers (21 ± 13 vs. 62 ± 23 /mm², p = 0.0068) than those in metastasis-negative cases. These findings suggest that HMGB1 produced by colon cancer cells suppressed nodal dendritic cells to disturb host anti-cancer immunity.

Introduction
Dendritic cells play a pivotal role in host immune response to various extrinsic microorganisms and also to cancer cells [1, 2]. The dendritic cells infiltrating into tumor tissues or in lymph nodes are sentries to the cancer antigens, which are recognized by dendritic cells and presented to T lymphocytes [3]. The presence of dendritic cells is associated with improved survival of colorectal cancer [4]. Dendritic cells are also expected to enhance host responses to cancer vaccination [5, 6].

In the present study, we showed that colon cancer escapes from the host anti-cancer immunity by interfering with the antigen-presenting process and decreasing of the number of dendritic cells. Dendritic cell densities in
primary and metastatic tumors are reported to be diminished significantly; however, the factors affecting dendritic cell inhibition are still unclear.

Peritoneal macrophage-derived dendritic cells (PMDCs) are induced from thioglycollate-stimulated murine peritoneal macrophages (PMs), which were induced to dendritic differentiation by treatment with the 2 cytokines (GM-CSF + IL-4), followed by IFN-γ + LPS [7]. PMDCs are reported to express MHC class II molecules at high level and attend to antigen presentation to CD3+ lymphocytes. PMDCs are useful for examining the dendritic cell response to cytokines.

HMGB1 is a dual role protein [9, 10], it plays roles in gene transcription [10] and DNA repair as a chromosome structure protein [11] and it is associated with neural development [12, 13], cancer progression and inflammation [10] as a secreted cytokine. In the immune system, HMGB1 is pivotal: it acts as a late inflammatory cytokine by activating macrophages in response to LPS [10] and it increases the secretion of inflammatory cytokines (IL-1β, IFN-γ, TNF-α) which worsen septic shock [14]. Furthermore, in various cancers, HMGB1 accelerates disease progression and metastasis by the activation of the specific receptor RAGE [15–20] and a high level of intratumoral HMGB1 induces apoptosis of tumor-associated macrophages, which is associated with lymph node metastasis of colon cancer [21, 22].

HMGB1 is released from loose chromatin in necrotic cells and diffuses into the extracellular milieu [23]. The lysates of dying cells induce the maturation of dendritic cells [24]. HMGB1 released from necrotic cells enhances antigen presentation by dendritic cells, leading to T cell immunity [25]. HMGB1 bound to DNA-containing necrotic substances is recognized by RAGE expressed in dendritic cells [26]. From these findings, we hypothesized that low concentrations of HMGB1 provide activation in monocytes and dendritic cells; however, high concentrations of HMGB1 might provide a death signal to dendritic cells, as found in macrophages. In this study, we attempt to reveal the inhibitory effect of HMGB1 on dendritic cells.

**Materials and Methods**

**Cell Culture**

Cells were maintained in RPMI-1640 medium (Sigma Chemical Co., St. Louis, Mo., USA) containing 10% FBS (Sigma) under conditions of 5% CO₂ in air at 37°C.

**Peritoneal Macrophage-Derived Dendritic Cells**

Four-week-old male C57BL mice (Japan SLC Inc., Shizuoka, Japan) were injected intraperitoneally with 1 ml of 10% thioglycollate (Becton-Dickinson Microbiology Systems, Sparks, Md., USA). On the 4th day, the rats were sacrificed and the peritoneal cavities were washed with cold PBS to collect infiltrated macrophages. The lavages were centrifuged, and the pellets were resuspended in 10% FBS supplemented RPMI-1640 medium. Suspend cells were cultured overnight. Adherent cells (peritoneal macrophages) were resuspended at 1 × 10⁶ cells per well in 24-well dishes. Dendritic cell differentiation was performed according to Makala et al. [7]. The peritoneal macrophages were treated with mouse recombinant interleukin-4 (Peprotec Ltd., London, UK; 1,000 U/ml) and mouse recombinant granulocyte-macrophage colony stimulating factor (Peprotec Ltd.; 1,000 U/ml) for 1 week. Then the cells were treated with mouse recombinant interferon-γ (Peprotec Ltd.; 250 U/ml) and LPS (Sigma; 250 μg/ml) for 72 h. Human recombinant HMGB1 was purchased from Abnova Corp. (Taipei City, Taiwan). For neutralization of HMGB1, anti-HMGB1 antibody (New England Biolabs Inc., Beverly, Mass., USA) was used. For cell labeling, PKH26 chemifluorescent dye (Zynaxis Inc., Malvern, Pa., USA) was used according to the provider’s instructions [21]. Infiltration of labeled cells was observed at 480 nm with a fluorescence microscope.

**Immunoblot Analysis**

Whole-cell lysates were prepared as described previously [27]. Fifty-microgram lysates were subjected to immunoblot analysis in 12.5% SDS-polyacrylamide gels followed by electrophoresis to nitrocellulose filters. The filters were incubated with primary antibody and then with peroxidase-conjugated IgG antibody (Medical and Biological Laboratories, Nagoya, Japan). A γ-tubulin antibody was used to assess the levels of protein loaded per lane (Oncogene Research Products, Cambridge, Mass., USA). The immune complex was visualized with an ECL Western-blot detection system (Amersham, Aylesbury, UK). Primary antibodies included anti-HMGB1 antibody (Upstate Biotechnology Inc., Lake Placid, N.Y., USA), and anti-phospho-JNK, anti-caspase 3, anti-caspase 9 antibodies (Santa-Cruz Biotechnology, Santa Cruz, Calif., USA), and anti-human CD205 (DEC-205) and anti-CD86 antibodies (Dako, Carpinteria, Calif., USA). CD86, a B-7 family ligand of CD28, a major T cell costimulatory receptor, is a marker of mature dendritic cells.

**Cell Growth**

Cells were seeded at a density of 10,000 cells per well in 24-well tissue culture plates. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma) was added to the culture medium at a concentration of 25 μg/ml for 30 min. After removal of the medium, 1 ml DMSO was added to dissolve formazan pigment, and 200 μl of the DMSO were examined at 540 nm. The experiments were performed in triplicate.

**Assessment of Apoptosis**

Apoptosis was assessed by staining with Hoechst33258 fluorescent dye (Wako Pure Chemical Industries Ltd., Osaka, Japan). The number of apoptotic cells was counted by observation of 1,000 cells.
Animal Model
C57BL mice were purchased from Japan SLC Inc. (Shizuoka, Japan). The mice were maintained according to institutional guidelines approved by the committee for animal experimentation of Nara Medical University, in accordance with the current regulations and standards of the Ministry of Health, Labour and Welfare. The mice were used according to the institutional guidelines when they were 5 weeks old. Human recombinant HMGB1 (500 μg/mouse) or PBS was administrated into each peritoneal cavity of 4 mice. Two days after the administration, mice were sacrificed and the spleens were taken for immunohistochemistry.

Surgical Specimens
Formalin-fixed, paraffin-embedded archival surgical specimens from 16 patients with primary colon adenocarcinomas that had invaded the subserosal layer were randomly selected from Miyoshi Central Hospital. Out of 16 cases, 8 were metastasis-negative (Dukes’ stage B), and 8 showed nodal metastasis (Dukes’ stage C). Because written informed consent was not obtained, identifying information for all samples was removed before analysis for strict privacy protection; the procedure was in accordance with the ethical guidelines for human genome/gene research enacted by the Japanese government.

Immunohistochemistry
Consecutive 4-μm sections were immunohistochemically stained using the immunoperoxidase technique described previously [15]. Anti-ED2 and anti-mouse CD205 (NLDC-145) antibodies (BMA Biomedicals, Augst, Switzerland) and anti-human CD205 (DEC-205) antibody (Dako) were used at a concentration of 0.5 μg/ml. CD205 is a mannose receptor-like membrane glycoprotein. CD205 is expressed in almost all types of dendritic cells. Secondary antibodies (Medical and Biological Laboratories) were used at a concentration of 0.2 μg/ml. The specimens were color-developed with diamine benzidine hydrochloride (Dako). Meyer’s hematoxylin (Sigma Chemical Co.) was used for counterstaining. For counting dendritic cells or macrophages, 20 high power fields containing lymph follicles and 20 high power fields containing paracortical areas and sinus were observed in each lymph node specimen. In tumor tissues, dendritic cells were counted from observation of 20 high power fields.

Enzyme-Linked Immunosorbent Assay (ELISA)
Cytosol/membrane fraction was used for ELISA assay. Frozen tissues of lymph nodes were minced and suspended with STKM buffer (50 mM Tris HCl pH 7.5, 25 mM KCl, 5 mM MgCl₂, 0.25 M sucrose, 10 μg/ml leupeptin, 50 μg/ml phenylmethylsulfonyl fluoride) and homogenized in Dounce-pestles by 150 strokes. After centrifugation at 1,000 g for 5 min, the supernatant was used for ELISA [28]. The pellet containing nuclear material was abandoned. HMGB1 concentration was detected by HMGB1 ELISA kit (Shinotest, Tokyo, Japan) according to the provider’s instructions.

Statistical Analysis
Statistical analyses of experimental data were carried out by Mann-Whitney U test and ANOVA test. Statistical significance was defined as a 2-sided p < 0.05.

HMGB1 Suppresses Dendritic Cells

<table>
<thead>
<tr>
<th>Table 1. Mean HMGB1 concentration and dendritic cell numbers in regional lymph nodes of 16 human colon cancer cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nodal metastasis</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>HMGB1, μg/g</td>
</tr>
<tr>
<td>Dendritic cells, n/mm²</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2. Mean HMGB1 concentration and dendritic cell numbers in primary lesions of 16 human colon cancer cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nodal metastasis</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>HMGB1, μg/g</td>
</tr>
<tr>
<td>Dendritic cells, n/mm²</td>
</tr>
</tbody>
</table>

Results

Dendritic Differentiation of Mouse Peritoneal Macrophages
To examine the effect of HMGB1 on dendritic cells, we induced dendritic differentiation of mouse peritoneal macrophages by sequential treatment with IL-4 + GM-CSF and IFN-γ + LPS. The PMDDCs showed larger size cell with dendritic processes (fig. 1b) in comparison with undifferentiated peritoneal macrophages (fig. 1a). Dendritic cell differentiation of PMs was confirmed by expression of CD86 and CD205 (fig. 1c). Expression of CD86 and CD206 was detected in PMDDCs but not in PMs.

Effect of HMGB1 on PMDDCs
HMGB1 treatment showed an inhibitory effect on both PMs and PMDDCs in a dose-dependent manner (fig. 2a). PMDDCs showed less sensitivity to HMGB1 than did PMs. To confirm the inhibitory effect of HMGB1 on PMDDCs, HMGB1 in the culture media was neutralized by specific antibody (fig. 2b–f) and the cells recovered from the HMGB1-induced inhibition.

Next we counted apoptotic cells treated by the HMGB1 in a dose-dependent manner (fig. 1g). HMGB1 increased phosphorylation of JNK and protein levels of caspases 3 and 9 (fig. 1h). Thus, HMGB1 inhibited PMDDCs by induction of JNK-associated apoptosis.
Effect of HMGB1 on Spleen Dendritic Cells in Mice

We next examined the effect of HMGB1 on dendritic cells in the spleens of mice (fig. 2). After administration of HMGB1 into the peritoneal cavity, the spleens were examined by immunohistochemistry. In HMGB1-treated mice, ED2-positive splenic resident macrophages were reduced to 37% of those in PBS-treated mice (fig. 2a) and CD205-positive dendritic cells were reduced to 53% (fig. 2a). Thus, the sensitivity of dendritic cells to HMGB1-induced inhibition is lower than that of macrophages.

HMGB1 Concentration and Dendritic Cells in Regional Lymph Nodes of Human Colon Cancer

In vitro and in the animal model, HMGB1 has an inhibitory effect on dendritic cells. To confirm the role of HMGB1 on colon cancer metastasis, the regional lymph nodes of 16 serosa-invading human colon cancers were examined for HMGB1 concentration and the number of dendritic cells by ELISA and immunohistochemistry (table 1, fig. 3). The nodal HMGB1 concentration (74 ± 23 μg/ml) of the 8 nodal metastasis-positive cases was higher than that of the 8 metastasis-negative lymph node cases (41 ± 15 μg/ml, p = 0.0116). The number of CD205-positive nodal dendritic cells (86 ± 22/mm²) was lower than that in metastasis-negative cases (137 ± 43/mm², p = 0.0224). HMGB1 concentrations in the regional lymph nodes were correlated with those in the primary tumors of the same cases (data not shown). Thus, nodal metastasis-positive cases showed higher nodal HMGB1 levels and lower numbers of nodal dendritic cells than those in metastasis-negative cases.

HMGB1 Concentration and Dendritic Cells in Primary Lesions of Human Colon Cancer

Finally, we examined the tumor HMGB1 concentration and the number of dendritic cells in primary tumor tissues in the 16 human colon cancer cases (table 2, fig. 3). Tumor tissues of metastasis-positive cases showed higher HMGB1 concentration (116 ± 33 vs. 37 ± 18 μg/ml, p =
0.0007) and lower CD205-positive dendritic cell numbers (21 ± 13 vs. 62 ± 23/mm², p = 0.0068) than those in metastasis-negative cases. Thus, nodal metastasis-positive cases showed higher tumor HMGB1 levels and lower numbers of intratumoral dendritic cells than those in metastasis-negative cases.

**Discussion**

HMGB1 is secreted from cancer cells and enhances cancer cell invasion and metastasis in colon cancer [16, 17]. HMGB1 secretion is increased by IL-15 and TGF-α, which are also secreted from cancer cells [29]. Thus,
HMGB1 acts as autocrine/paracrine tumor growth factor in colon cancer.

We also reported that HMGB1 possesses a pro-apoptotic effect on macrophages [21]. Colon cancers producing high levels of HMGB1 result in fewer tumor-associated macrophages and higher frequency of nodal metastasis [22]. Thus, HMGB1 produced from colon cancer cells show 2 effects: cancer cell progression and macrophage inhibition, which might accelerate disease progression in colon cancer.

Our next question was whether HMGB1 has some other effects on monocyte-lineage immune cells. In the present study, we revealed that HMGB1 inhibits dendritic cells by inducing apoptosis, which is associated with lymph node metastasis of colon cancer. We have previously shown that HMGB1 provides JNK phosphorylation in PMA-induced macrophage-differentiated U937 cells, which causes apoptosis. In PMDDCs, HMGB1 also provided JNK phosphorylation with increases in caspases 3 and 9, which are associated with apoptotic signals.

Dendritic cells possess a key role as antigen presenting cells in the specific immune system. Dysfunction of dendritic cells provides an impairment of immune response to specific antigens. In anti-cancer host immunity, dendritic cells in tumor tissues and the regional lymph nodes act as antigen presenting cells against cancer. Decreases in dendritic cells in the tumor tissues and lymph nodes might weaken the host’s anti-cancer immune responses. Our results suggest that cancer-derived HMGB1 inhibits dendritic cells and might suppress a wide range of the host’s anti-cancer immune responses, which could contribute to metastasis to lymph nodes or distant organs. Further studies should examine effects of HMGB1 on distant metastasis of cancers.

In the present study, we examined monocytic dendritic cells but not plasmacytoid dendritic cells, which act as interdigitating cells in lymph nodes. HMGB1 is reported to be a maturation factor for plasmacytoid dendritic cells. HMGB1 showed different effects on macrophages: a low level of HMGB1 activates macrophages to secrete inflammatory cytokines [10, 14] and a high level of HMGB1 induces apoptosis of macrophages [21]. Therefore, a high level of HMGB1 might induce apoptosis of plasmacytoid dendritic cells.

In conclusion, HMGB1 shows obvious suppressive effects on the host’s anti-cancer immunity and might be an important target for molecular therapy for colorectal cancer.

**Acknowledgement**

This work was supported in part by a grant-in-aid for scientific research from the Ministry of Health, Labour and Welfare, Japan.
References


